Opus Genetics, Inc. (IRD) Operating Margin
- Operating margin · 12 months: Value -513.47%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -513.47% | Operating income / revenue. Period ending 2026-06-30. $-50.61M ÷ $9.86M × 100 ≈ -513.47% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -50.61M USD | Operating Income (Loss) |
| Revenue | 9.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-50.61M | $9.86M | (m) | (m) | (m) | -513.47% |
| 2026-03-31 | $-43.03M | $11.98M | (m) | (m) | (m) | -359.13% |
| 2025-12-31 | $-38.60M | $14.20M | (m) | (m) | (m) | -271.90% |
| 2025-09-30 | $-65.17M | $14.63M | (m) | (m) | (m) | -445.40% |
| 2025-06-30 | $-64.87M | $15.42M | (m) | (m) | (m) | -420.68% |
| 2025-03-31 | $-64.30M | $13.65M | (m) | (m) | (m) | -470.99% |
| 2024-12-31 | $-62.07M | $10.99M | (m) | (m) | (m) | -564.72% |
| 2024-09-30 | $-29.47M | $8.38M | (m) | (m) | (m) | -351.68% |
| 2024-06-30 | $-15.08M | $16.45M | (m) | (m) | (m) | -91.67% |
| 2024-03-31 | $-12.14M | $19.01M | (m) | (m) | (m) | -63.86% |
| 2023-12-31 | $-10.56M | $19.05M | (m) | (m) | (m) | -55.45% |
| 2023-09-30 | $29.08M | $57.21M | (m) | (m) | (m) | 50.83% |
| 2023-06-30 | $18.15M | $45.27M | (m) | (m) | (m) | 40.09% |
| 2023-03-31 | $18.60M | $41.60M | (m) | (m) | (m) | 44.72% |
| 2022-12-31 | $18.23M | $39.85M | (m) | (m) | (m) | 45.74% |
| 2022-09-30 | $-22.13M | $0.00 | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-21.83M | $489.00K | (m) | (m) | (m) | -4463.80% |
| 2022-03-31 | $-24.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-22.70M | $589.00K | (m) | (m) | (m) | -3854.84% |
| 2021-09-30 | $-30.58M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-28.29M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-22.42M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-19.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-6.43M | (m) | (m) | $1.29M | (m) | (m) |
| 2020-06-30 | $-7.20M | (m) | (m) | $2.27M | (m) | (m) |
| 2020-03-31 | $-7.84M | (m) | (m) | $3.69M | (m) | (m) |
| 2019-12-31 | $-11.22M | (m) | (m) | $5.48M | (m) | (m) |
| 2019-09-30 | $-14.17M | (m) | (m) | $7.75M | (m) | (m) |
| 2019-06-30 | $-16.58M | (m) | (m) | $9.51M | (m) | (m) |
| 2019-03-31 | $-18.59M | (m) | (m) | $11.29M | (m) | (m) |
| 2018-12-31 | $-20.54M | (m) | (m) | $13.11M | (m) | (m) |
| 2018-09-30 | $-20.47M | (m) | (m) | $13.64M | (m) | (m) |
| 2018-06-30 | $-20.00M | (m) | (m) | $13.40M | (m) | (m) |
| 2018-03-31 | $-19.29M | (m) | (m) | $12.51M | (m) | (m) |
| 2017-12-31 | $-17.35M | (m) | (m) | $10.72M | (m) | (m) |
| 2017-09-30 | $-16.38M | (m) | (m) | $9.54M | (m) | (m) |
| 2017-06-30 | $-15.87M | (m) | (m) | $9.19M | (m) | (m) |
| 2017-03-31 | $-15.50M | (m) | (m) | $8.88M | (m) | (m) |
| 2016-12-31 | $-16.41M | (m) | (m) | $10.09M | (m) | (m) |
| 2016-09-30 | $-16.86M | (m) | (m) | $10.92M | (m) | (m) |
| 2016-06-30 | $-17.80M | (m) | (m) | $11.73M | (m) | (m) |
| 2016-03-31 | $-18.71M | (m) | (m) | $12.72M | (m) | (m) |
| 2015-12-31 | $-18.26M | (m) | (m) | $12.15M | (m) | (m) |
| 2015-09-30 | $-17.75M | (m) | (m) | $11.45M | (m) | (m) |
| 2015-06-30 | $-16.23M | (m) | (m) | $10.17M | (m) | (m) |
| 2015-03-31 | $-14.92M | (m) | (m) | $8.64M | (m) | (m) |
| 2014-12-31 | $-13.27M | (m) | (m) | $7.02M | (m) | (m) |
| 2014-09-30 | $-11.75M | (m) | (m) | $5.79M | (m) | (m) |
| 2014-06-30 | $-10.43M | (m) | (m) | $4.75M | (m) | (m) |
| 2014-03-31 | $-8.84M | $0.00 | (m) | $3.97M | (m) | (m) |
| 2013-12-31 | $-7.98M | $0.00 | (m) | $3.25M | (m) | (m) |
| 2013-09-30 | $-6.69M | (m) | (m) | $2.52M | (m) | (m) |
| 2013-06-30 | $-6.67M | (m) | (m) | $2.81M | (m) | (m) |
| 2013-03-31 | $-6.60M | (m) | (m) | $2.90M | (m) | (m) |
| 2012-12-31 | $-6.58M | (m) | (m) | $3.39M | (m) | (m) |
| 2012-09-30 | $-7.94M | (m) | (m) | $4.61M | (m) | (m) |
| 2012-06-30 | $-9.49M | $0.00 | (m) | $5.92M | (m) | (m) |
| 2012-03-31 | $-14.10M | $0.00 | (m) | $10.32M | (m) | (m) |
| 2011-12-31 | $-16.13M | $0.00 | (m) | $11.99M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-10.31M | $0.00 | (m) | $3.93M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-6.47M | $0.00 | (m) | $3.18M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |